Symbols / ABT
ABT Chart
About
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company provides pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Medical Devices | Market Cap | 195.38B |
| Enterprise Value | 200.76B | Income | 6.52B | Sales | 44.33B |
| Book/sh | 29.30 | Cash/sh | 4.45 | Dividend Yield | 224.00% |
| Payout | 63.44% | Employees | 115000 | IPO | — |
| P/E | 30.18 | Forward P/E | 17.98 | PEG | — |
| P/S | 4.41 | P/B | 3.83 | P/C | — |
| EV/EBITDA | 17.47 | EV/Sales | 4.53 | Quick Ratio | — |
| Current Ratio | — | Debt/Eq | 25.31 | LT Debt/Eq | — |
| EPS (ttm) | 3.72 | EPS next Y | 6.24 | EPS Growth | -80.80% |
| Revenue Growth | 4.40% | Earnings | 2026-04-15 | ROA | — |
| ROE | 13.16% | ROIC | — | Gross Margin | 56.71% |
| Oper. Margin | 22.03% | Profit Margin | 14.72% | Shs Outstand | 1.74B |
| Shs Float | 1.73B | Short Float | 1.08% | Short Ratio | 1.67 |
| Short Interest | — | 52W High | 141.23 | 52W Low | 105.27 |
| Beta | 0.75 | Avg Volume | 9.10M | Volume | 6.44M |
| Target Price | $133.39 | Recom | Buy | Prev Close | $112.68 |
| Price | $112.26 | Change | -0.37% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$133.39
Mean price target
2. Current target
$112.26
Latest analyst target
3. DCF / Fair value
$55.80
Fallback: EPS × 15 (assumed fair P/E). No FCF data; use with …
Ratings
Current target
$112.26
Low
$113.00
High
$158.00
Mean
$133.39
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-02 | main | Barclays | Overweight → Overweight | $142 |
| 2026-01-23 | main | Citigroup | Buy → Buy | $140 |
| 2026-01-23 | main | Bernstein | Outperform → Outperform | $125 |
| 2026-01-23 | main | RBC Capital | Outperform → Outperform | $135 |
| 2026-01-23 | main | Oppenheimer | Outperform → Outperform | $132 |
| 2026-01-23 | main | Evercore ISI Group | Outperform → Outperform | $138 |
| 2026-01-23 | main | Piper Sandler | Overweight → Overweight | $135 |
| 2026-01-23 | main | BTIG | Buy → Buy | $140 |
| 2026-01-09 | main | Bernstein | Outperform → Outperform | $154 |
| 2026-01-05 | main | Barclays | Overweight → Overweight | $169 |
| 2025-11-20 | reit | BTIG | Buy → Buy | $145 |
| 2025-10-17 | main | Barclays | Overweight → Overweight | $162 |
| 2025-10-16 | main | Raymond James | Outperform → Outperform | $146 |
| 2025-10-16 | main | Evercore ISI Group | Outperform → Outperform | $142 |
| 2025-10-16 | reit | RBC Capital | Outperform → Outperform | $147 |
| 2025-10-16 | main | Wells Fargo | Overweight → Overweight | $146 |
| 2025-10-15 | reit | BTIG | Buy → Buy | $145 |
| 2025-10-10 | init | Benchmark | — → Buy | $145 |
| 2025-10-07 | main | Evercore ISI Group | Outperform → Outperform | $144 |
| 2025-09-10 | main | Bernstein | Outperform → Outperform | $138 |
News
RSS: Latest ABT news- NEOS Investment Management LLC Acquires 72,502 Shares of Abbott Laboratories $ABT - MarketBeat ue, 17 Feb 2026 12
- Why Abbott Laboratories (ABT) Shares Are Sliding Today - Yahoo Finance hu, 22 Jan 2026 08
- Abbott Laboratories (ABT) Stock Analysis: 18% Potential Upside Beckons Investors - DirectorsTalk Interviews Mon, 16 Feb 2026 14
- Is The Fall In Abbott Stock Justified? - Forbes Fri, 23 Jan 2026 08
- Abbott Laboratories Stock Now 19% Cheaper, Time To Buy - Trefis Wed, 28 Jan 2026 08
- Insider Purchase: CHAIRMAN AND CEO of $ABT Buys 18,800 Shares | ABT Stock News - Quiver Quantitative Mon, 26 Jan 2026 08
- Investors - Abbott Fri, 12 Dec 2025 04
- Skandinaviska Enskilda Banken AB publ Buys 190,255 Shares of Abbott Laboratories $ABT - MarketBeat ue, 17 Feb 2026 11
- Could The Market Be Wrong About Abbott Laboratories (NYSE:ABT) Given Its Attractive Financial Prospects? - Yahoo Finance Sun, 15 Feb 2026 11
- Abbott Laboratories $ABT Shares Purchased by Vanguard Group Inc. - MarketBeat Mon, 16 Feb 2026 12
- NVST or ABT: Which Is the Better Value Stock Right Now? - Yahoo Finance Mon, 02 Feb 2026 08
- Pallas Capital Advisors LLC Reduces Stock Position in Abbott Laboratories $ABT - MarketBeat Mon, 16 Feb 2026 11
- Shell Asset Management Co. Trims Stock Position in Abbott Laboratories $ABT - MarketBeat Mon, 16 Feb 2026 11
- M&G PLC Buys New Shares in Abbott Laboratories $ABT - MarketBeat Mon, 16 Feb 2026 12
- Fifth Third Bancorp Sells 10,616 Shares of Abbott Laboratories $ABT - MarketBeat Mon, 16 Feb 2026 09
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 10000 | 1087331 | — | Purchase at price 108.33 - 109.14 per share. | STARKS DANIEL J | Director | — | 2026-02-04 00:00:00 | D |
| 1 | 18800 | 2013967 | — | Purchase at price 107.13 per share. | FORD ROBERT B. | Chief Executive Officer | — | 2026-01-23 00:00:00 | I |
| 2 | 1536 | 189358 | — | Stock Gift at price 123.28 per share. | SALVADORI DANIEL GESUA SIVE | Officer | — | 2025-12-11 00:00:00 | D |
| 3 | 1586 | 203043 | — | Sale at price 128.02 per share. | SHROFF ERIC | Officer | — | 2025-11-25 00:00:00 | D |
| 4 | 5550 | 746758 | — | Sale at price 134.55 per share. | BOUDREAU PHILIP P | Chief Financial Officer | — | 2025-08-08 00:00:00 | D |
| 5 | 3790 | — | — | Stock Award(Grant) at price 0.00 per share. | CUSHMAN ELIZABETH C | General Counsel | — | 2025-06-27 00:00:00 | D |
| 6 | 2600 | 337116 | — | Sale at price 129.66 per share. | BLOUNT SALLY E | Director | — | 2025-04-30 00:00:00 | D |
| 7 | 1635 | — | — | Stock Award(Grant) at price 0.00 per share. | BABINEAUX CLAIRE FONTENOT | Director | — | 2025-04-25 00:00:00 | D |
| 8 | 1635 | — | — | Stock Award(Grant) at price 0.00 per share. | MCDEW DARREN W | Director | — | 2025-04-25 00:00:00 | D |
| 9 | 1635 | — | — | Stock Award(Grant) at price 0.00 per share. | GONZALEZ PATRICIA PAOLA | Director | — | 2025-04-25 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 5.67M | -5.78M | -330.60K | -139.00K |
| TaxRateForCalcs | 0.21 | 0.14 | 0.17 | 0.14 |
| NormalizedEBITDA | 10.76B | 10.59B | 12.13B | 12.28B |
| TotalUnusualItems | 27.00M | -41.00M | -2.00M | -1.00M |
| TotalUnusualItemsExcludingGoodwill | 27.00M | -41.00M | -2.00M | -1.00M |
| NetIncomeFromContinuingOperationNetMinorityInterest | 13.40B | 5.72B | 6.93B | 7.07B |
| ReconciledDepreciation | 3.22B | 3.24B | 3.27B | 3.54B |
| ReconciledCostOfRevenue | 17.37B | 16.70B | 17.89B | 17.05B |
| EBITDA | 10.79B | 10.54B | 12.13B | 12.28B |
| EBIT | 7.57B | 7.30B | 8.86B | 8.74B |
| NetInterestIncome | -215.00M | -252.00M | -375.00M | -490.00M |
| InterestExpense | 559.00M | 637.00M | 558.00M | 533.00M |
| InterestIncome | 344.00M | 385.00M | 183.00M | 43.00M |
| NormalizedIncome | 13.38B | 5.76B | 6.93B | 7.07B |
| NetIncomeFromContinuingAndDiscontinuedOperation | 13.40B | 5.72B | 6.93B | 7.07B |
| TotalExpenses | 35.12B | 33.63B | 35.29B | 34.65B |
| TotalOperatingIncomeAsReported | 6.83B | 6.48B | 8.36B | 8.43B |
| DilutedAverageShares | 1.75B | 1.75B | 1.75B | 1.76B |
| BasicAverageShares | 1.74B | 1.73B | 1.73B | 1.74B |
| DilutedEPS | 3.72 | 7.64 | 3.26 | 3.91 |
| BasicEPS | 3.75 | 7.74 | 3.30 | 3.99 |
| DilutedNIAvailtoComStockholders | 13.40B | 5.72B | 6.93B | 7.07B |
| NetIncomeCommonStockholders | 13.40B | 5.72B | 6.93B | 7.07B |
| NetIncome | 13.40B | 5.72B | 6.93B | 7.07B |
| NetIncomeIncludingNoncontrollingInterests | 13.40B | 5.72B | 6.93B | 7.07B |
| NetIncomeDiscontinuousOperations | 0.00 | 0.00 | ||
| NetIncomeContinuousOperations | 13.40B | 5.72B | 6.93B | 7.07B |
| TaxProvision | -6.39B | 941.00M | 1.37B | 1.14B |
| PretaxIncome | 7.01B | 6.66B | 8.31B | 8.21B |
| OtherIncomeExpense | 403.00M | 438.00M | 319.00M | 276.00M |
| OtherNonOperatingIncomeExpenses | 376.00M | 479.00M | 321.00M | 277.00M |
| SpecialIncomeCharges | 0.00 | |||
| GainOnSaleOfSecurity | 27.00M | -41.00M | -2.00M | -1.00M |
| NetNonOperatingInterestIncomeExpense | -215.00M | -252.00M | -375.00M | -490.00M |
| InterestExpenseNonOperating | 559.00M | 637.00M | 558.00M | 533.00M |
| InterestIncomeNonOperating | 344.00M | 385.00M | 183.00M | 43.00M |
| OperatingIncome | 6.83B | 6.48B | 8.36B | 8.43B |
| OperatingExpense | 16.42B | 15.66B | 16.15B | 16.11B |
| DepreciationAmortizationDepletionIncomeStatement | 1.88B | 1.97B | 2.01B | 2.05B |
| DepreciationAndAmortizationInIncomeStatement | 1.88B | 1.97B | 2.01B | 2.05B |
| Amortization | 1.88B | 1.97B | 2.01B | 2.05B |
| AmortizationOfIntangiblesIncomeStatement | 1.88B | 1.97B | 2.01B | 2.05B |
| ResearchAndDevelopment | 2.84B | 2.74B | 2.89B | 2.74B |
| SellingGeneralAndAdministration | 11.70B | 10.95B | 11.25B | 11.32B |
| GrossProfit | 23.24B | 22.13B | 24.51B | 24.54B |
| CostOfRevenue | 18.71B | 17.98B | 19.14B | 18.54B |
| TotalRevenue | 41.95B | 40.11B | 43.65B | 43.08B |
| OperatingRevenue | 41.95B | 40.11B | 43.65B | 43.08B |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TreasurySharesNumber | 259.77M | 253.81M | 248.72M | 221.19M |
| OrdinarySharesNumber | 1.73B | 1.73B | 1.74B | 1.76B |
| ShareIssued | 1.99B | 1.99B | 1.99B | 1.99B |
| NetDebt | 6.51B | 7.78B | 6.89B | 8.25B |
| TotalDebt | 15.02B | 15.63B | 17.72B | 19.01B |
| TangibleBookValue | 17.91B | 6.11B | 3.43B | -168.00M |
| InvestedCapital | 61.79B | 53.28B | 53.46B | 53.85B |
| WorkingCapital | 9.50B | 8.83B | 9.73B | 11.13B |
| NetTangibleAssets | 17.91B | 6.11B | 3.43B | -168.00M |
| CapitalLeaseObligations | 896.00M | 949.00M | 943.00M | 956.00M |
| CommonStockEquity | 47.66B | 38.60B | 36.69B | 35.80B |
| TotalCapitalization | 60.29B | 52.20B | 51.21B | 53.10B |
| TotalEquityGrossMinorityInterest | 47.90B | 38.83B | 36.91B | 36.02B |
| MinorityInterest | 237.00M | 224.00M | 219.00M | 222.00M |
| StockholdersEquity | 47.66B | 38.60B | 36.69B | 35.80B |
| GainsLossesNotAffectingRetainedEarnings | -7.91B | -7.84B | -8.05B | -8.37B |
| OtherEquityAdjustments | -7.91B | -7.84B | -8.05B | -8.37B |
| TreasuryStock | 16.84B | 15.98B | 15.23B | 11.82B |
| RetainedEarnings | 47.26B | 37.55B | 35.26B | 31.53B |
| CapitalStock | 25.15B | 24.87B | 24.71B | 24.47B |
| CommonStock | 25.15B | 24.87B | 24.71B | 24.47B |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 33.51B | 34.39B | 37.53B | 39.17B |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 19.36B | 20.55B | 22.04B | 26.07B |
| OtherNonCurrentLiabilities | 2.37B | 2.39B | 3.80B | 3.69B |
| EmployeeBenefits | 1.88B | 1.96B | 1.78B | 2.74B |
| NonCurrentPensionAndOtherPostretirementBenefitPlans | 1.88B | 1.96B | 1.78B | 2.74B |
| TradeandOtherPayablesNonCurrent | 1.07B | 1.08B | ||
| NonCurrentDeferredLiabilities | 512.00M | 568.00M | 991.00M | 1.39B |
| NonCurrentDeferredTaxesLiabilities | 512.00M | 568.00M | 991.00M | 1.39B |
| LongTermDebtAndCapitalLeaseObligation | 13.52B | 14.55B | 15.46B | 18.25B |
| LongTermCapitalLeaseObligation | 896.00M | 949.00M | 943.00M | 956.00M |
| LongTermDebt | 12.62B | 13.60B | 14.52B | 17.30B |
| CurrentLiabilities | 14.16B | 13.84B | 15.49B | 13.11B |
| CurrentDebtAndCapitalLeaseObligation | 1.50B | 1.08B | 2.25B | 754.00M |
| CurrentDebt | 1.50B | 1.08B | 2.25B | 754.00M |
| PayablesAndAccruedExpenses | 12.66B | 12.76B | 13.24B | 12.35B |
| CurrentAccruedExpenses | 6.22B | 6.37B | 6.76B | 6.44B |
| Payables | 6.43B | 6.39B | 6.47B | 5.91B |
| OtherPayable | 621.00M | 650.00M | 638.00M | 364.00M |
| DividendsPayable | 1.02B | 955.00M | 887.00M | 831.00M |
| TotalTaxPayable | 594.00M | 492.00M | 343.00M | 306.00M |
| IncomeTaxPayable | 594.00M | 492.00M | 343.00M | 306.00M |
| AccountsPayable | 4.20B | 4.29B | 4.61B | 4.41B |
| TotalAssets | 81.41B | 73.21B | 74.44B | 75.20B |
| TotalNonCurrentAssets | 57.76B | 50.54B | 49.21B | 50.96B |
| OtherNonCurrentAssets | 16.46B | 7.10B | 6.03B | 5.21B |
| NonCurrentDeferredAssets | 6.03B | 5.21B | ||
| NonCurrentDeferredTaxesAssets | 6.03B | 5.21B | ||
| InvestmentsAndAdvances | 886.00M | 799.00M | 766.00M | 816.00M |
| OtherInvestments | 333.00M | 244.00M | 208.00M | |
| InvestmentinFinancialAssets | 553.00M | 555.00M | 558.00M | |
| AvailableForSaleSecurities | 553.00M | 555.00M | 558.00M | |
| GoodwillAndOtherIntangibleAssets | 29.75B | 32.49B | 33.25B | 35.97B |
| OtherIntangibleAssets | 6.65B | 8.81B | 10.45B | 12.74B |
| Goodwill | 23.11B | 23.68B | 22.80B | 23.23B |
| NetPPE | 10.66B | 10.15B | 9.16B | 8.96B |
| AccumulatedDepreciation | -12.08B | -11.78B | -11.05B | -10.40B |
| GrossPPE | 22.74B | 21.93B | 20.21B | 19.36B |
| ConstructionInProgress | 2.49B | 2.06B | 1.48B | 1.30B |
| OtherProperties | 15.52B | 15.18B | 14.16B | 13.53B |
| MachineryFurnitureEquipment | 13.53B | |||
| BuildingsAndImprovements | 4.21B | 4.16B | 4.05B | 4.01B |
| LandAndImprovements | 528.00M | 529.00M | 511.00M | 525.00M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 23.66B | 22.67B | 25.22B | 24.24B |
| PrepaidAssets | 2.35B | |||
| Inventory | 6.19B | 6.57B | 6.17B | 5.16B |
| FinishedGoods | 3.70B | 3.95B | 3.81B | 3.08B |
| WorkInProcess | 840.00M | 807.00M | 680.00M | 694.00M |
| RawMaterials | 1.65B | 1.82B | 1.69B | 1.38B |
| Receivables | 9.49B | 8.82B | 8.88B | 8.83B |
| OtherReceivables | 2.57B | 2.26B | 2.66B | 2.35B |
| AccountsReceivable | 6.92B | 6.57B | 6.22B | 6.49B |
| AllowanceForDoubtfulAccountsReceivable | -439.00M | -444.00M | -500.00M | -519.00M |
| GrossAccountsReceivable | 7.36B | 7.01B | 6.72B | 7.01B |
| CashCashEquivalentsAndShortTermInvestments | 7.97B | 7.28B | 10.17B | 10.25B |
| OtherShortTermInvestments | 351.00M | 383.00M | 288.00M | 450.00M |
| CashAndCashEquivalents | 7.62B | 6.90B | 9.88B | 9.80B |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | 6.35B | 5.06B | 7.80B | 8.65B |
| RepurchaseOfCapitalStock | -1.29B | -1.23B | -3.79B | -2.30B |
| RepaymentOfDebt | -660.00M | -2.50B | -753.00M | -48.00M |
| IssuanceOfDebt | 223.00M | 2.00M | 7.00M | 4.00M |
| CapitalExpenditure | -2.21B | -2.20B | -1.78B | -1.89B |
| InterestPaidSupplementalData | 604.00M | 662.00M | 563.00M | 544.00M |
| IncomeTaxPaidSupplementalData | 1.72B | 1.48B | 1.86B | 1.94B |
| EndCashPosition | 7.62B | 6.90B | 9.88B | 9.80B |
| BeginningCashPosition | 6.90B | 9.88B | 9.80B | 6.84B |
| EffectOfExchangeRateChanges | -96.00M | -23.00M | -122.00M | -70.00M |
| ChangesInCash | 816.00M | -2.96B | 205.00M | 3.03B |
| FinancingCashFlow | -5.40B | -7.09B | -7.64B | -5.49B |
| CashFlowFromContinuingFinancingActivities | -5.40B | -7.09B | -7.64B | -5.49B |
| ProceedsFromStockOptionExercised | 264.00M | 167.00M | 167.00M | 255.00M |
| CashDividendsPaid | -3.84B | -3.56B | -3.31B | -3.20B |
| CommonStockDividendPaid | -3.84B | -3.56B | -3.31B | -3.20B |
| NetCommonStockIssuance | -1.29B | -1.23B | -3.79B | -2.30B |
| CommonStockPayments | -1.29B | -1.23B | -3.79B | -2.30B |
| NetIssuancePaymentsOfDebt | -537.00M | -2.48B | -699.00M | -248.00M |
| NetShortTermDebtIssuance | -100.00M | 21.00M | 47.00M | -204.00M |
| NetLongTermDebtIssuance | -437.00M | -2.50B | -746.00M | -44.00M |
| LongTermDebtPayments | -660.00M | -2.50B | -753.00M | -48.00M |
| LongTermDebtIssuance | 223.00M | 2.00M | 7.00M | 4.00M |
| InvestingCashFlow | -2.34B | -3.13B | -1.74B | -2.01B |
| CashFlowFromContinuingInvestingActivities | -2.34B | -3.13B | -1.74B | -2.01B |
| NetOtherInvestingChanges | 9.00M | 22.00M | 22.00M | 26.00M |
| NetInvestmentPurchaseAndSale | -141.00M | -116.00M | -33.00M | -96.00M |
| SaleOfInvestment | 28.00M | 43.00M | 152.00M | 77.00M |
| PurchaseOfInvestment | -169.00M | -159.00M | -185.00M | -173.00M |
| NetBusinessPurchaseAndSale | 1.00M | -837.00M | 48.00M | -53.00M |
| SaleOfBusiness | 1.00M | 40.00M | 48.00M | 134.00M |
| PurchaseOfBusiness | 0.00 | -877.00M | 0.00 | -187.00M |
| NetPPEPurchaseAndSale | -2.21B | -2.20B | -1.78B | -1.89B |
| PurchaseOfPPE | -2.21B | -2.20B | -1.78B | -1.89B |
| OperatingCashFlow | 8.56B | 7.26B | 9.58B | 10.53B |
| CashFlowFromContinuingOperatingActivities | 8.56B | 7.26B | 9.58B | 10.53B |
| ChangeInWorkingCapital | -9.22B | -2.48B | -1.52B | -771.00M |
| ChangeInOtherWorkingCapital | -585.00M | -383.00M | -908.00M | |
| ChangeInPayablesAndAccruedExpense | -7.67B | -1.34B | 37.00M | 1.29B |
| ChangeInPayable | -7.67B | -1.34B | 37.00M | 1.29B |
| ChangeInAccountPayable | 356.00M | -760.00M | 420.00M | 1.29B |
| ChangeInTaxPayable | -8.03B | -585.00M | -383.00M | -908.00M |
| ChangeInIncomeTaxPayable | -8.03B | -585.00M | -383.00M | -908.00M |
| ChangeInPrepaidAssets | -796.00M | -542.00M | -75.00M | -312.00M |
| ChangeInInventory | -58.00M | -232.00M | -1.41B | -456.00M |
| ChangeInReceivables | -691.00M | -356.00M | -68.00M | -383.00M |
| ChangesInAccountReceivables | -691.00M | -356.00M | -68.00M | -383.00M |
| StockBasedCompensation | 673.00M | 644.00M | 685.00M | 640.00M |
| DepreciationAmortizationDepletion | 3.22B | 3.24B | 3.27B | 3.54B |
| DepreciationAndAmortization | 3.22B | 3.24B | 3.27B | 3.54B |
| AmortizationCashFlow | 1.88B | 1.97B | 2.01B | 2.05B |
| AmortizationOfIntangibles | 1.88B | 1.97B | 2.01B | 2.05B |
| Depreciation | 1.34B | 1.28B | 1.25B | 1.49B |
| OperatingGainsLosses | 482.00M | 126.00M | 215.00M | 55.00M |
| GainLossOnInvestmentSecurities | 482.00M | 126.00M | 215.00M | 55.00M |
| NetIncomeFromContinuingOperations | 13.40B | 5.72B | 6.93B | 7.07B |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for ABT
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|